Angle plc has announced
a technological advancement that could extend the capability of its Parsortix diagnostic to treat cancer patients. The company’s noninvasive test captures and counts rare circulating tumor cells, or CTCs, from patients’ blood. A new process Angle has developed for recovering captured cells from the Parsortix cassette itself will enable analysis by a range of molecular techniques. The breakthrough holds the possibility of new diagnostic, prognostic, and treatment applications for cancer patients, the company says.
No other diagnostic available has the potential to recover intact CTCs, according to Angle. Because CTC analysis is noninvasive, there is no need to perform tumor biopsies, the company says. Angle is working with the Paterson Institute for Cancer Research in Manchester, UK, to explore use of the Parsortix system as a source of CTCs for cancer-treating medical applications.
Angle’s CEO, Andrew Newland, says the worldwide market for Parsortix CTC capture applications is more than £6 billion ($9.5 billion) annually. Headquartered in Guilford, UK, Angle hopes to receive regulatory approval for the clinical market in 2013.